LOD, Israel--(BUSINESS WIRE)-- TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today that it is replacing the name of its drug delivery system from ViaDerm to ViaDor™. The new name better reflects TransPharma's enhanced commercialization efforts and global collaborations.
ViaDor or the "golden path" expresses the capabilities of TransPharma’s system to introduce drugs to the systemic circulation without pain or discomfort and also alludes to the transdermal "doors" - the microscopic channels the system creates in the upper layer of the skin that enable an efficient delivery of a wide array of drug-molecules.
The new name also serves to disassociate TransPharma's drug delivery system from other products carrying the name ViaDerm, thus preventing confusion.
"The new name that we have chosen for our transdermal drug delivery system is a natural consequence of TransPharma's increasing success and expansion," said Dr. Daphna Heffetz, CEO of TransPharma Medical. "It not only helps to showcase the various beneficial characteristics of our system, but also serves to better differentiate our technology. The ViaDor system is currently being studied in advanced-stage clinical trials for three distinct drug products: ViaDor-hPTH (1-34) for the treatment of osteoporosis, in collaboration with Eli Lilly; ViaDor-GLP1 agonist for the treatment of type II diabetes; and ViaDor-Calcitonin for the treatment of musculoskeletal diseases."
About the Self Applied ViaDor Drug Delivery System
TransPharma’s ViaDor drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. The system provides a cost-effective, easy-to-use, virtually pain-free, self-administered solution that enables the safe, reproducible and accurate delivery of a broad range of product candidates, including hydrophilic small molecule such as peptides and proteins.
About TransPharma Medical
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing its proprietary active transdermal drug delivery technology. The company aims to develop multiple drug products through strategic partnerships with leading pharmaceutical companies and through independent product development. TransPharma currently has 3 drug products in clinical trials: ViaDor-hPTH (1-34) product for the treatment of osteoporosis developed in collaboration with Eli Lilly and currently in Phase 2b clinical studies; ViaDor-GLP1 agonist for the treatment of type II diabetes that has completed phase 1b clinical study; and the ViaDor-Calcitonin that has completed a Phase 1 clinical trial. For more information, please visit the Company's website at www.transpharma-medical.com.
CONTACT:
TransPharma Medical Ltd.
Tsipi Haitovsky
Media Liaison
+972-52-598-9892
[email protected]
KEYWORDS: United States North America New York Middle East Israel
INDUSTRY KEYWORDS: Health Biotechnology Medical Devices Pharmaceutical Other Health Medical Supplies
MEDIA:
| Logo |